<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">9106549</journal-id>
<journal-id journal-id-type="pubmed-jr-id">2198</journal-id>
<journal-id journal-id-type="nlm-ta">Clin Auton Res</journal-id>
<journal-id journal-id-type="iso-abbrev">Clin. Auton. Res.</journal-id>
<journal-title-group>
<journal-title>Clinical autonomic research : official journal of the Clinical Autonomic Research Society</journal-title>
</journal-title-group>
<issn pub-type="ppub">0959-9851</issn>
<issn pub-type="epub">1619-1560</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28667575</article-id>
<article-id pub-id-type="pmc">5722227</article-id>
<article-id pub-id-type="doi">10.1007/s10286-017-0438-2</article-id>
<article-id pub-id-type="manuscript">NIHMS893894</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Animal and cellular models of familial dysautonomia</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Lefcort</surname>
<given-names>Frances</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="author-notes" rid="FN1">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mergy</surname>
<given-names>Marc</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ohlen</surname>
<given-names>Sarah B.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ueki</surname>
<given-names>Yumi</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>George</surname>
<given-names>Lynn</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
</contrib-group>
<aff id="A1">
<label>1</label>Department of Cell Biology and Neuroscience, Montana State University, Bozeman, MT 59717</aff>
<aff id="A2">
<label>2</label>Department of Biological and Physical Sciences, Montana State University Billings, Billings, MT 59101</aff>
<author-notes>
<corresp id="FN1"><label>*</label>Corresponding author: Frances Lefcort, Ph.D, Department of Cell Biology and Neuroscience, Montana State University, Bozeman, MT 59717, Tel: 406.994.5656, <email>lefcort@montana.edu</email>, ORCHID number: 0000-0002-2064-8678</corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>22</day>
<month>7</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>30</day>
<month>6</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="ppub">
<month>8</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>8</month>
<year>2018</year>
</pub-date>
<volume>27</volume>
<issue>4</issue>
<fpage>235</fpage>
<lpage>243</lpage>
<!--elocation-id from pubmed: 10.1007/s10286-017-0438-2-->
<abstract>
<p id="P1">Since Riley and Day first described the clinical phenotype of patients with familial dysautonomia (FD) over 60 years ago, the field has made considerable progress clinically, scientifically, and translationally in treating and understanding the etiology of FD. FD is classified as a hereditary sensory and autonomic neuropathy (HSAN Type III) and is both a developmental and a progressive neurodegenerative condition that results from an autosomal recessive mutation in the gene <italic>IKBKAP</italic>, also known as <italic>ELP1.</italic> FD primarily impacts the peripheral nervous system but also manifests in central nervous system disruption, especially in the retina and optic nerve. While the disease is rare, the rapid progress being made in elucidating the molecular and cellular mechanisms mediating the demise of neurons in FD should provide insight into degenerative pathways common to many neurological disorders. Interestingly, the protein encoded by <italic>IKBKAP/ELP1,</italic> IKAP or ELP1, is a key scaffolding subunit of the six-subunit Elongator complex, and variants in other Elongator genes are associated with amyotrophic lateral sclerosis (ALS), intellectual disability, and Rolandic Epilepsy. Here we review the recent model systems that are revealing the molecular and cellular pathophysiological mechanisms mediating FD. These powerful model systems can now be used to test targeted therapeutics for mitigating neuronal loss in FD and potentially other disorders.</p>
</abstract>
</article-meta>
</front>
</article>
</pmc-articleset>